Nothing Special   »   [go: up one dir, main page]

PL1608346T3 - Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania - Google Patents

Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania

Info

Publication number
PL1608346T3
PL1608346T3 PL04759681T PL04759681T PL1608346T3 PL 1608346 T3 PL1608346 T3 PL 1608346T3 PL 04759681 T PL04759681 T PL 04759681T PL 04759681 T PL04759681 T PL 04759681T PL 1608346 T3 PL1608346 T3 PL 1608346T3
Authority
PL
Poland
Prior art keywords
alpha
acid ester
hydroxy acid
methods
drug delivery
Prior art date
Application number
PL04759681T
Other languages
English (en)
Inventor
John M Lipari
Michelle A Long
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PL1608346T3 publication Critical patent/PL1608346T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04759681T 2003-03-31 2004-03-19 Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania PL1608346T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/403,071 US20040191207A1 (en) 2003-03-31 2003-03-31 Alpha-hydroxy acid ester drug delivery compositions and methods of use
PCT/US2004/008417 WO2004093851A1 (en) 2003-03-31 2004-03-19 Alpha-hydroxy acid ester drug delivery compositions and methods of use
EP04759681A EP1608346B1 (en) 2003-03-31 2004-03-19 Alpha-hydroxy acid ester drug delivery compositions and methods of use

Publications (1)

Publication Number Publication Date
PL1608346T3 true PL1608346T3 (pl) 2009-07-31

Family

ID=32989847

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04759681T PL1608346T3 (pl) 2003-03-31 2004-03-19 Kompozycje dostarczające lek zawierające estry alfa-hydroksykwasów i sposób ich zastosowania

Country Status (14)

Country Link
US (1) US20040191207A1 (pl)
EP (1) EP1608346B1 (pl)
JP (2) JP5005339B2 (pl)
AT (1) ATE413865T1 (pl)
CA (1) CA2518918C (pl)
CY (1) CY1108700T1 (pl)
DE (1) DE602004017705D1 (pl)
DK (1) DK1608346T3 (pl)
ES (1) ES2317017T3 (pl)
MX (1) MXPA05010607A (pl)
PL (1) PL1608346T3 (pl)
PT (1) PT1608346E (pl)
SI (1) SI1608346T1 (pl)
WO (1) WO2004093851A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
DE102010013064A1 (de) 2010-03-26 2011-12-15 Gabriele Blume Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然複合ホルモン補充製剤および療法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP7314459B2 (ja) 2017-11-27 2023-07-26 ウメクリン コグニチオン アーべー 3α-エチニル-3β-ヒドロキシアンドロスタン-17-オンオキシムの医薬製剤
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492325A (en) * 1967-03-24 1970-01-27 Procter & Gamble Production of alpha-hydroxy acids and esters
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
SK277092A3 (en) * 1992-09-07 1996-08-07 Galena As Medicaments with n-methylated cyclic undecapeptides
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
CA2185600A1 (en) * 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
CN1261794A (zh) * 1997-07-01 2000-08-02 辉瑞产品公司 增溶的舍曲林组合物
US6284268B1 (en) * 1997-12-10 2001-09-04 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0010354A (pt) * 1999-05-07 2002-03-05 Pharmasol Gmbh Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção
WO2000074652A1 (de) * 1999-06-02 2000-12-14 Hexal Ag Pharmazeutische zusammensetzung zur nasalen anwendung von wasserlöslichen wirkstoffen
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations

Also Published As

Publication number Publication date
JP2006522105A (ja) 2006-09-28
MXPA05010607A (es) 2005-11-23
ES2317017T3 (es) 2009-04-16
CA2518918A1 (en) 2004-11-04
CY1108700T1 (el) 2014-04-09
DE602004017705D1 (de) 2008-12-24
EP1608346B1 (en) 2008-11-12
SI1608346T1 (sl) 2009-04-30
PT1608346E (pt) 2009-02-06
WO2004093851A1 (en) 2004-11-04
DK1608346T3 (da) 2009-01-26
JP5592905B2 (ja) 2014-09-17
JP2012136521A (ja) 2012-07-19
US20040191207A1 (en) 2004-09-30
CA2518918C (en) 2011-08-09
JP5005339B2 (ja) 2012-08-22
EP1608346A1 (en) 2005-12-28
ATE413865T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
PH12012500765A1 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
UA94052C2 (uk) Похідні піридазину
MEP18208A (en) Immune response modifier foam formulations
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MX349769B (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
TW200621317A (en) Pharmaceutical composition
GB9800526D0 (en) Organic compounds
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
MX2010005714A (es) Compuestos de piridina.
WO2010033726A3 (en) Drug delivery composition comprising a self-assembled gelator
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
MY142792A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
ZA200805598B (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
MX2007006775A (es) Composiciones estables de fenofibrato con esteres de acido graso.
IL182835A0 (en) Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
ATE402706T1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon